In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models

Journal of Immunotherapy

Volumn 30, Issue 7, 2007, Pages 715-726

  Kretz Rommel, Anke ^a   Qin, Fenghua ^a   Dakappagari, Naveen ^a   Torensma, Ruurd ^b   Faas, Susan ^c   Wu, Dayang ^c   Bowdish, Katherine S ^a  

^a Alexion Antibody Technologies Inc   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ALEXION PHARMACEUTICALS   (United States)

Author keywords

Antibodies; Dendritic cells; Vaccination

Indexed keywords

5G1.1 ANTIBODY; ADJUVANT; ANTIBODY CONJUGATE; CD209 ANTIGEN; CD40 ANTIGEN; CRL 8941; D1V1 ANTIBODY; FLUDARABINE; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE; TETANUS TOXOID; TITERMAX; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL TRANSPLANTATION; CONJUGATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAJI CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELLS; HEMOCYANIN; HUMANS; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 34748840807     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318135472c     Document Type: Article

References (36)

1. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
3. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189:371-380.
4. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med. 2002;195:1653-1659.
5. Biragyn A, Ruffini PA, Coscia M, et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood. 2004;104:1961-1969.
6. Bonifaz L, Bonnyay D, Mahnke K, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627-1638.
7. Ramakrishna V, Treml JF, Vitale L, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol. 2004;172:2845-2852.
8. Mahnke K, Qian Y, Fondel S, et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 2005;65:7007-7012.
9. Carter RW, Thompson C, Reid DM, et al. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol. 2006;177:2276-2284.
10. Carter RW, Thompson C, Reid DM, et al. Induction of CD8+ T cell responses through targeting of antigen to Dectin-2. Cell Immunol. 2006;239:87-91.
11. Tacken PJ, de Vries IJ, Gijzen K, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood. 2005;106:1278-1285.
12. Park CG, Takahara K, Umemoto E, et al. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol. 2001;13:1283-1290.
13. Takahara K, Yashima Y, Omatsu Y, et al. Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int Immunol. 2004;16:819-829.
14. Caminschi I, Corbett AJ, Zahra C, et al. Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN. Int Immunol. 2006;18:741-753.
15. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304:104-107.
16. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214-5220.
17. Krug LM, Ragupathi G, Hood C, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res. 2004;10:6094-6100.
18. Slovin SF. Prostate-specific membrane antigen vaccines: naked DNA and protein approaches. Clin Prostate Cancer. 2005;4:118-123.
19. Evans MJ, Rollins SA, Wolff DW, et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol. 1995;32:1183-1195.
20. Dakappagari N, Maruyama T, Renshaw M, et al. Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J Immunol. 2006;176:426-440.
21. Howland KC, Ausubel LJ, London CA, et al. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol. 2000;164:4465-4470.
22. Hafner M, Zawatzky R, Hirtreiter C, et al. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 2001;61:5523-5528.
23. Caparros E, Munoz P, Sierra-Filardi E, et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood. 2006;107:3950-3958.
24. Rieser C, Ramoner R, Holtl L, et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int. 1999;63:151-159.
25. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses anti-tumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178:5595-5605.
26. Tary-Lehmann M, Saxon A, Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunol Today. 1995;16:529-533.
27. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
28. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-1016.
29. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969-1980.
30. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
31. Schreurs MW, Eggert AA, Punt CJ, et al. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncog. 2000;11:1-17.
32. Bozzacco L, Trumpfheller C, Siegal FP, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104:1289-1294.
33. Croce MV, Segal-Eiras A. The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer. Drugs Today (Barc). 2002;38:759-768.
34. Millard AL, Ittelet D, Schooneman F, et al. Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine. 2003;21:869-876.
35. Kato M, McDonald KJ, Khan S, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol. 2006;18:857-869.
36. Mueller JP, Giannoni MA, Hartman SL, et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol. 1997;34:441-452.